Autolus Therapeutics plc — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Autolus reported Q2 2026 net product revenue of $45.7 million (vs. $20.9M in Q2 2025), a 119% year-over-year increase driven by AUCATZYL adoption across 82+ U.S. authorized treatment centers and UK market entry. The company raised FY 2026 guidance to $140–$150 million (from $120–$135M). Gross margin improved to 55% in Q2 from 6% in Q1, supported by higher volumes and cost reductions. Autolus secured a five-year, interest-only credit facility of up to $250 million from Perceptive Advisors ($75M funded at close; $25M optionally available; $150M on achievement of revenue milestones), strengthening cash runway to Q2 2028.
Why this rating
Strong commercial traction (119% YoY growth) and margin expansion are meaningful for a $549M market-cap company; $250M credit facility substantially improves runway and removes near-term financing risk; guidance raise confirms execution. Offset by ongoing net losses ($39M in Q2) and pipeline uncertainty—not yet transformational.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.